Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches

A Negi, AS Voisin‐Chiret - ChemBioChem, 2022 - Wiley Online Library
Apoptosis is a highly regulated cellular process. Aberration in apoptosis is a common
characteristic of various disorders. Therefore, proteins involved in apoptosis are prime …

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

J Chang, Y Wang, L Shao, RM Laberge, M Demaria… - Nature medicine, 2016 - nature.com
Senescent cells (SCs) accumulate with age and after genotoxic stress, such as total-body
irradiation (TBI),,,,,. Clearance of SCs in a progeroid mouse model using a transgenic …

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity

D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang… - Nature …, 2021 - nature.com
Abstract PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug
development platform. However, most PROTACs have been generated empirically because …

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr …

J Kuroda, S Kimura, A Strasser, M Andreeff… - Cell Death & …, 2007 - nature.com
Bcr-Abl is the cause of Philadelphia-positive (Ph+) leukemias and also constitutes their
principal therapeutic target, as exemplified by dramatic effects of imatinib mesylate …

[HTML][HTML] Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

F Liu, Q Zhao, Y Su, J Lv, Y Gai, S Liu, H Lin… - Experimental …, 2022 - Elsevier
Acute myeloid leukemia (AML) remains a clinical challenge. Venetoclax is an effective Bcl-2
selective inhibitor approved by the US Food and Drug Administration (FDA) for treatment of …

Selective targeting of antiapoptotic BCL‐2 proteins in cancer

AC Timucin, H Basaga, O Kutuk - Medicinal research reviews, 2019 - Wiley Online Library
Circumvention of apoptotic machinery is one of the distinctive properties of carcinogenesis.
Extensively established key effectors of such apoptotic bypass mechanisms, the …

[HTML][HTML] Stayin'alive: BCL-2 proteins in the hematopoietic system

PMA Zehnle, Y Wu, H Pommerening… - Experimental …, 2022 - Elsevier
Highlights•Antiapoptotic BCL-2 proteins are essential to maintain the hematopoietic
system.•BCL-2 protein dependency varies between the different blood cell lineages.•BH3 …

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

S Beurlet, N Omidvar, P Gorombei… - Blood, The Journal …, 2013 - ashpublications.org
Myelodysplastic syndrome (MDS) transforms into an acute myelogenous leukemia (AML)
with associated increased bone marrow (BM) blast infiltration. Using a transgenic mouse …

Targeting BCL-2 in hematologic malignancies

N Khan, B Kahl - Targeted Oncology, 2018 - Springer
Resistance to apoptosis is one of the hallmarks of cancer and members of the B-cell
lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers …

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies–from pathogenesis to treatment

M Vogler, HS Walter, MJS Dyer - British journal of haematology, 2017 - Wiley Online Library
The B‐cell lymphoma 2 (BCL 2) family of proteins comprise key regulators of apoptosis and
are implicated in the pathogenesis of many malignancies, including lymphomas and …